Heart health check for kids after childhood cancer treatment
Part of Blood & lymphatic, Cancer, Heart & circulation clinical trials.
This trial checks how anthracycline chemotherapy affects the heart and blood vessels in children and teens who had cancer. It aims to help doctors better understand long-term heart risks and follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with cancer between birth and age 16.
- You are now 6 years old or older.
- You received anthracycline chemotherapy as part of your cancer treatment.
- Your cancer is in remission (no signs of disease) for at least 1 year.
- You did not have any heart problems before taking anthracycline.
- You do not have any heart condition you were born with.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how cancer therapies affect the heart health of children. It aims to find heart problems early using special tests, so doctors can help prevent damage.
This study checks how a common chemotherapy drug (anthracycline) affects the heart in children. It will monitor heart function during treatment to help protect young patients.
This study looks at how chemotherapy and other cancer treatments affect the heart in children. It aims to find heart problems early so they can be treated quickly.
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
This study checks heart health in adult survivors of childhood cancer who had certain heart-related treatments years ago. If you haven't had a heart ultrasound in the last 5 years, you may be able to help researchers learn how to better monitor heart health.
This study follows people who had cancer as children to learn about heart-related changes years after treatment. It may help doctors better understand who is at risk and how to monitor the heart in long-term survivors.
Hear when a new Chemotherapeutic Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.